WO2003076627A1 - Process for the preparation of l-amino acids using strains of the family enterobacteriaceae - Google Patents

Process for the preparation of l-amino acids using strains of the family enterobacteriaceae Download PDF

Info

Publication number
WO2003076627A1
WO2003076627A1 PCT/EP2003/001997 EP0301997W WO03076627A1 WO 2003076627 A1 WO2003076627 A1 WO 2003076627A1 EP 0301997 W EP0301997 W EP 0301997W WO 03076627 A1 WO03076627 A1 WO 03076627A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene coding
gene
coding
threonine
microorganisms
Prior art date
Application number
PCT/EP2003/001997
Other languages
French (fr)
Inventor
Mechthild Rieping
Thomas Hermann
Mike Farwick
Original Assignee
Degussa Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002110966 external-priority patent/DE10210966A1/en
Application filed by Degussa Ag filed Critical Degussa Ag
Priority to DE60321891T priority Critical patent/DE60321891D1/en
Priority to EP03708152A priority patent/EP1483387B1/en
Publication of WO2003076627A1 publication Critical patent/WO2003076627A1/en
Priority to US10/937,554 priority patent/US20050095687A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/12—Methionine; Cysteine; Cystine

Definitions

  • the present invention relates to a process for the preparation of L-amino acids, especially L-threonine, using strains of the family Enterobacteriaceae in which the mglB gene is enhanced.
  • L-Amino acids especially L-threonine
  • L-threonine are used in human medicine and in the pharmaceutical industry, in the food industry and very particularly in animal nutrition.
  • the productivity characteristics of these microorganisms are improved by using methods of mutagenesis, selection and mutant choice to give strains which are resistant to antimetabolites, e.g. the threonine analog ⁇ -amino- ⁇ - hydroxyvaleric acid (AHV) , or auxotrophic for metabolites of regulatory significance, and produce L-amino acids, e.g. L-threonine.
  • antimetabolites e.g. the threonine analog ⁇ -amino- ⁇ - hydroxyvaleric acid (AHV)
  • auxotrophic for metabolites of regulatory significance e.g. L-threonine.
  • Methods of recombinant DNA technology have also been used for some years to improve L-amino acid-producing strains of the family Enterobacteriaceae by amplifying individual amino acid biosynthesis genes and studying the effect on production.
  • the object which the inventors set themselves was to provide novel procedures for improving the preparation of L-amino acids, especially L-threonine.
  • the invention provides a process for the preparation of L- a ino acids, especially L-threonine, using microorganisms of the family Enterobacteriaceae which, in particular, already produce L-amino acids and in which the nucleotide sequence coding for the mglB gene is enhanced.
  • L-amino acids or “amino acids” mentioned hereafter is to be understood as meaning one or more amino acids, including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isoleucine, L-leucine, L-tyrosine, L- phenylalanine, L-histidine, L-lysine, L-tryptophan and L- arginine.
  • L-Threonine is particularly preferred.
  • the term "enhancement” describes the increase, in a microorganism, of the intracellular activity of one or more enzymes or proteins coded for by the appropriate DNA, for example by increasing the copy number of the gene or genes, using a strong promoter or a gene or allele coding for an appropriate enzyme or protein with a high activity, and optionally combining these measures.
  • the activity or concentration of the appropriate protein is generally increased at least by 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, and at most by up to 1000% or 2000%, based on that of the wild- type protein or the activity or concentration of the protein in the starting microorganism.
  • the microorganisms provided by the present invention can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch or optionally cellulose, or from glycerol and ethanol .
  • Said microorganisms are representatives of the family
  • Enterobacteriaceae selected from the genera Escherichia, Erwinia, Providencia and Serratia.
  • the genera Escherichia and Serratia are preferred.
  • the species Escherichia coli and Serratia marcescens may be mentioned in particular among the genera Escherichia and Serratia respectively.
  • suitable strains particularly L-threonine- producing strains, of the genus Escherichia, and especially of the species Escherichia coli, are:
  • L-threonine-producing strains of the genus Serratia and especially of the species Serratia marcescens, are:
  • L-Threonine-producing strains of the family Enterobacteriaceae preferably possess, inter alia, one or more genetic or phenotypic characteristics selected from the group comprising resistance to ⁇ -amino- ⁇ -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to ⁇ -methylserine, resistance to diaminosuccinic acid, resistance to ⁇ -aminobutyric acid, resistance to borrelidine, resistance to rifampicin, resistance to valine analogs such as valine hydroxamate, resistance to purine analogs such as 6-dimethylaminopurine, need for L- methionine, optionally partial and compensable need for L- isoleucine, need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methion
  • the nucleotide sequences of the genes of Escherichia coli belong to the state of the art (cf. literature references below) and can also be taken from the genome sequence of Escherichia coli published by Blattner et al . (Science 277, 1453-1462 (1997)).
  • the mglB gene is described inter alia by the following data:
  • the nucleic acid sequences can be taken from the data banks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA) , the nucleotide sequence data bank of the European Molecular Biologies Laboratories (EMBL, Heidelberg, Germany, or Cambridge, UK) or the DNA Databank of Japan (DDBJ, Mishima, Japan) .
  • NCBI National Center for Biotechnology Information
  • EMBL European Molecular Biologies Laboratories
  • EMBL European Molecular Biologies Laboratories
  • DDBJ Mishima, Japan
  • genes described in the literature references cited can be used according to the invention. It is also possible to use alleles of the genes which result from the degeneracy of the genetic code or from neutral sense mutations . The use of endogenous genes is preferred.
  • endogenous genes or “endogenous nucleotide sequences” is to be understood as meaning the genes or alleles, or nucleotide sequences, present in the population of a species.
  • Enhancement can be achieved for example by increasing the expression of the genes or enhancing the catalytic properties of the proteins. Both measures may optionally be combined.
  • the concentration of the transport protein coded for by the polynucleotide mglB can be determined by the method described by Richarme and Caldas (Journal of Biological Chemistry 272, 15607-15612 (1997)).
  • Over-expression can be achieved by increasing the copy number of the appropriate genes or mutating the promoter and regulatory region or the ribosome binding site located upstream from the structural gene.
  • Expression cassettes incorporated upstream from the structural gene work in the same way.
  • Inducible promoters additionally make it possible to increase expression in the course of L- threonine production by fermentation. Measures for prolonging the life of the RNA also improve expression.
  • the enzyme activity is also enhanced by preventing the degradation of the enzyme protein.
  • the genes or gene constructs can either be located in plasmids of variable copy number or be integrated and amplified in the chromosome. Alternatively, it is also possible to achieve over-expression of the genes in question by changing the composition of the media and the culture technique.
  • Plasmid vectors replicable in Enterobacteriaceae e.g. cloning vectors derived from pACYC184 (Bartolome et al . ; Gene 102, 75-78 (1991)), pTrc99A (Amann et al . ; Gene 69,
  • mutations which affect the expression of the appropriate genes can be transferred to different strains by sequence exchange (Hamilton et al . (Journal of
  • L-amino acids especially L-threonine
  • strains of the family Enterobacteriaceae it can be advantageous not only to enhance the mglB gene but also to enhance one or more enzymes of the known threonine biosynthetic pathway, or enzymes of the anaplerotic metabolism, or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate, or glycolytic enzymes, or PTS enzymes or enzymes of sulfur metabolism.
  • endogenous genes is preferred.
  • sucA gene of the sucABCD operon coding for the decarboxylase subunit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2) , 351-359 (1984))
  • sucB gene of the sucABCD operon coding for the dihydrolipoyl transsuccinase E2 subunit of 2- ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2), 361-374 (1984))
  • sucC gene of the sucABCD operon coding for the ⁇ subunit of succinyl-CoA synthetase (Biochemistry 24 (22), 6245-6252 (1985))
  • sucD gene of the sucABCD operon coding for the ⁇ subunit of succinyl-CoA synthetase (Biochemistry 24 (22), 6245-6252 (1985))
  • L-amino acids especially L-threonine
  • the term "attenuation” describes the decrease or switching-off of the intracellular activity, in a microorganism, of one or more enzymes (proteins) coded for by the appropriate DNA, for example by using a weak promoter or using a gene or allele which codes for an appropriate enzyme with a low activity or inactivates the appropriate enzyme (protein) or gene, and optionally combining these measures .
  • the attenuation measures generally reduce the activity or concentration of the appropriate protein to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
  • L-amino acids especially L-threonine
  • it can be advantageous not only to enhance the mglB gene but also to switch off unwanted secondary reactions Nakayama: “Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982.
  • the microorganisms prepared according to the invention can be cultivated by the batch process, the fed batch process or the repeated fed batch process.
  • a summary of known cultivation methods is provided in the textbook by Chmiel (Bioreatechnik 1. Einbowung in die Biovonstechnik (Bioprocess Technology 1. Introduction to Bioengineering) (Gustav Fischer Verlag, Stuttgart, 1991) ) or in the textbook by Storhas (Bioreaktoren und periphere bamboo (Bioreactors and Peripheral Equipment) (Vieweg Verlag, Brunswick/Wiesbaden, 1994) ) .
  • the culture medium to be used must appropriately meet the demands of the particular strains. Descriptions of culture media for various microorganisms can be found in "Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington DC, USA, 1981) .
  • Carbon sources which can be used are sugars and carbohydrates, e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, e.g. palmitic acid, stearic acid and linoleic acid, alcohols, e.g. glycerol and ethanol , and organic acids, e.g. acetic acid. These substances can be used individually or as a mixture.
  • sugars and carbohydrates e.g. glucose, sucrose, lactose, fructose, maltose, molasses
  • starch e.g. cellulose
  • oils and fats e.g. soya oil, sunflower oil, groundnut oil and coconut fat
  • fatty acids e.g. palmitic acid, stearic acid and linoleic acid
  • alcohols e.g
  • Nitrogen sources which can be used are organic nitrogen- containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate.
  • the nitrogen sources can be used individually or as a mixture.
  • Phosphorus sources which can be used are phosphoric acid, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium salts .
  • the culture medium must also contain metal salts, e.g. magnesium sulfate or iron sulfate, which are necessary for growth.
  • metal salts e.g. magnesium sulfate or iron sulfate, which are necessary for growth.
  • essential growth-promoting substances such as amino acids and vitamins can be used in addition to the substances mentioned above.
  • Suitable precursors can also be added to the culture medium. Said feed materials can be added to the culture all at once or fed in appropriately during cultivation.
  • the pH of the culture is controlled by the appropriate use of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds such as phosphoric acid or sulfuric acid. Foaming can be controlled using antifoams such as fatty acid polyglycol esters.
  • the stability of plasmids can be maintained by adding suitable selectively acting substances, e.g. antibiotics, to the medium. Aerobic conditions are maintained by introducing oxygen or oxygen-containing gaseous mixtures, e.g. air, into the culture.
  • the temperature of the culture is normally 25 a C to 45 2 C and preferably 30 2 C to 40 -C .
  • the culture is continued until the formation of L-amino acids or L-threonine has reached a maximum. This objective is normally achieved within 10 hours to 160 hours.
  • L-Amino acids can be analyzed by means of anion exchange chromatography followed by ninhydrin derivation, as described by Spackman et al . (Analytical Chemistry 30, 1190 (1958)), or by reversed phase HPLC, as described by Lindroth et al . (Analytical Chemistry 51, 1167-1174 (1979) ) .
  • L-amino acids e.g. L-threonine, L- isoleucine, L-valine, L-methionine, L-homoserine and L- lysine, especially L-threonine, by fermentation.
  • M9 and complete medium (LB) used for Escherichia coli are described by J.H. Miller (A Short Course in Bacterial Genetics (1992), Cold Spring Harbor Laboratory Press) .
  • the isolation of plasmid DNA from Escherichia coli and all the techniques for restriction, ligation, Klenow treatment and alkaline phosphatase treatment are carried out according to Sambrook et al . (Molecular Cloning - A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press) . Unless described otherwise, the transformation of Escherichia coli is carried out according to Chung et al . (Proceedings of the National Academy of Sciences of the United States of America 86, 2172-2175 (1989)).
  • the incubation temperature in the preparation of strains and transformants is 37°C.
  • the mglB gene from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides .
  • PCR polymerase chain reaction
  • the nucleotide sequence of the mglB gene in E. coli K12 MG1655 (Accession Number AE000304, Blattner et al. (Science 277, 1453-1474 (1997)) is used as the starting material to synthesize PCR primers (MWG Biotech, Ebersberg, Germany) .
  • the sequences of the 5' ends of the primers are modified to create recognition sites for restriction enzymes.
  • the recognition sequences for Xbal and Hindlll, which are underlined in the nucleotide sequence shown below, are chosen for the mglBl and mglB2 primers respectively:
  • mglBl 5'-CCTGCTCTAGATAAACCGGAGATACCATG-3 ' (SEQ ID No . 1)
  • mglB2 5'-CCGAAGCTTGTTGGCCATACAATAAGGGCG-3 ' (SEQ ID No . 2)
  • the chromosomal E. coli K12 MG1655 DNA used for the PCR is isolated with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions.
  • An approx. 1100 bp DNA fragment can be amplified with the specific primers under standard PCR conditions (Innis et al . (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) using pfu DNA polymerase (Promega Corporation, Madison, USA) .
  • the PCR product is cleaved with the restriction enzymes Xbal and Hindlll and ligated with vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) that has been digested with the enzymes Xbal and Hindlll.
  • the E. coli strain XLl-Blue MRF ' (Stratagene, La Jolla, USA) is transformed with the ligation mixture and plasmid-carrying cells are selected on LB agar supplemented with 50 ⁇ g/ml of ampicillin.
  • the success of the cloning can be demonstrated, after isolation of the plasmid D ⁇ A, by control cleavage with the enzymes Xbal, Hindlll, EcoRI and Hpal .
  • the plasmid is called pTrc99AmglB ( Figure 1) .
  • the L-threonine-producing E. coli strain MG442 is described in patent US-A-4, 278 , 765 and is deposited in the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia) as CMIM B-1628.
  • the strain MG442 is transformed with expression plasmid pTrc99AmglB, described in Example 1, and with vector pTrc99A and plasmid-carrying cells are selected on LB agar supplemented with 50 ⁇ g/ml of ampicillin. This procedure yields the strains MG442/pTrc99AmglB and MG442/pTrc99A.
  • 250 ⁇ l of each of these precultures are transferred to 10 ml of production medium (25 g/1 of (NH ) 2 S0 , 2 g/1 of KH 2 P0 , 1 g/1 of MgS0 4 -7H 2 0, 0.03 g/1 of FeS0 4 -7H 2 0, 0.018 g/1 of MnS0 -lH 2 0, 30 g/1 of CaC0 3 , 20 g/1 of glucose, 50 mg/1 of ampicillin) and incubated for 48 hours at 37°C.
  • the formation of L-threonine by the original strain MG442 is verified in the same way except that no ampicillin is added to the medium.
  • the optical density (OD) of the culture suspension is determined using an LP2W photometer from Dr. Lange (Berlin, Germany) at a measurement wavelength of 660 nm.
  • the concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by means of ion exchange chromatography and postcolumn reaction with ninhydrin detection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)

Abstract

The invention relates to a process for the preparation of L-amino acids, especially L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the family Enterobacteriaceae which produce the desired L-amino acid and in which the mglB gene, or nucleotide sequences coding therefor, is (are) enhanced and, in particular, overexpressed, b) enrichment of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the desired L-amino acid.

Description

Process for the Preparation of -Amino Acids using Strains of the Family Enterobacteriaceae
Field of the Invention
The present invention relates to a process for the preparation of L-amino acids, especially L-threonine, using strains of the family Enterobacteriaceae in which the mglB gene is enhanced.
State of the Art
L-Amino acids, especially L-threonine, are used in human medicine and in the pharmaceutical industry, in the food industry and very particularly in animal nutrition.
It is known to prepare L-amino acids by the fermentation of strains of Enterobacteriaceae, especially Escherichia coli (E. coli) and Serratia marcescens. Because of their great importance, attempts are constantly being made to improve the preparative processes . Improvements to the processes may relate to measures involving the fermentation technology, e.g. stirring and oxygen supply, or the composition of the nutrient media, e.g. the sugar concen- tration during fermentation, or the work-up to the product form, e.g. by ion exchange chro atography, or the intrinsic productivity characteristics of the microorganism itself.
The productivity characteristics of these microorganisms are improved by using methods of mutagenesis, selection and mutant choice to give strains which are resistant to antimetabolites, e.g. the threonine analog α-amino-β- hydroxyvaleric acid (AHV) , or auxotrophic for metabolites of regulatory significance, and produce L-amino acids, e.g. L-threonine.
Methods of recombinant DNA technology have also been used for some years to improve L-amino acid-producing strains of the family Enterobacteriaceae by amplifying individual amino acid biosynthesis genes and studying the effect on production.
Object of the Invention
The object which the inventors set themselves was to provide novel procedures for improving the preparation of L-amino acids, especially L-threonine.
Summary of the Invention
The invention provides a process for the preparation of L- a ino acids, especially L-threonine, using microorganisms of the family Enterobacteriaceae which, in particular, already produce L-amino acids and in which the nucleotide sequence coding for the mglB gene is enhanced.
Detailed Description of the Invention
The term "L-amino acids" or "amino acids" mentioned hereafter is to be understood as meaning one or more amino acids, including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isoleucine, L-leucine, L-tyrosine, L- phenylalanine, L-histidine, L-lysine, L-tryptophan and L- arginine. L-Threonine is particularly preferred.
In this context the term "enhancement" describes the increase, in a microorganism, of the intracellular activity of one or more enzymes or proteins coded for by the appropriate DNA, for example by increasing the copy number of the gene or genes, using a strong promoter or a gene or allele coding for an appropriate enzyme or protein with a high activity, and optionally combining these measures.
Through the measures of enhancement, especially over- expression, the activity or concentration of the appropriate protein is generally increased at least by 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, and at most by up to 1000% or 2000%, based on that of the wild- type protein or the activity or concentration of the protein in the starting microorganism.
The process is characterized in that the following steps are carried out:
a) fermentation of microorganisms of the family Enterobacteriaceae in which the mglB gene is enhanced,
b) enrichment of the appropriate L-amino acid in the medium or in the cells of the microorganisms of the family
Enterobacteriaceae, and
c) isolation of the desired L-amino acid, where constituents of the fermentation broth, and/or all or part (> 0 to 100%) of the biomass, optionally remain in the product.
The microorganisms provided by the present invention can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch or optionally cellulose, or from glycerol and ethanol . Said microorganisms are representatives of the family
Enterobacteriaceae selected from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. The species Escherichia coli and Serratia marcescens may be mentioned in particular among the genera Escherichia and Serratia respectively.
Examples of suitable strains, particularly L-threonine- producing strains, of the genus Escherichia, and especially of the species Escherichia coli, are:
Escherichia coli TF427 Escherichia coli H4578
Escherichia coli KY10935
Escherichia coli VNIIgenetika MG442 Escherichia coli VNIIgenetika Ml
Escherichia coli VNIIgenetika 472T23
Escherichia coli BKIIM B-3996
Escherichia coli kat 13 Escherichia coli KCCM-10132
Examples of suitable L-threonine-producing strains of the genus Serratia, and especially of the species Serratia marcescens, are:
Serratia marcescens HΝr21 Serratia marcescens TLrl56 Serratia marcescens T2000.
L-Threonine-producing strains of the family Enterobacteriaceae preferably possess, inter alia, one or more genetic or phenotypic characteristics selected from the group comprising resistance to α-amino-β-hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α-methylserine, resistance to diaminosuccinic acid, resistance to α-aminobutyric acid, resistance to borrelidine, resistance to rifampicin, resistance to valine analogs such as valine hydroxamate, resistance to purine analogs such as 6-dimethylaminopurine, need for L- methionine, optionally partial and compensable need for L- isoleucine, need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L- glutamic acid, resistance to L-aspartate, resistance to L- leucine, resistance to L-phenylalanine, resistance to L- serine, resistance to L-cysteine, resistance to L-valine, sensitivity to fluoropyruvate, defective threonine dehydrogenase, optionally capability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feedback-resistant form, enhancement of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the feedback-resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenolpyruvate carboxylase, optionally of the feedback-resistant form, enhancement of phosphoenolpyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase and attenuation of acetic acid formation.
It has been found that the production of L-amino acids, especially L-threonine, by microorganisms of the family Enterobacteriaceae is improved after enhancement and, in particular, over-expression of the mglB gene.
The nucleotide sequences of the genes of Escherichia coli belong to the state of the art (cf. literature references below) and can also be taken from the genome sequence of Escherichia coli published by Blattner et al . (Science 277, 1453-1462 (1997)).
The mglB gene is described inter alia by the following data:
Name: periplasmatic galactose-binding transport protein, receptor for galactose chemotaxis
Reference: Hogg et al . ; Molecular and General Genetics 229, 453-459 (1991)
Muller et al . ; Molecular and General Genetics 185, 473-480 (1982)
Accession no.: AE000304
Alternative name: dgaL
The nucleic acid sequences can be taken from the data banks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA) , the nucleotide sequence data bank of the European Molecular Biologies Laboratories (EMBL, Heidelberg, Germany, or Cambridge, UK) or the DNA Databank of Japan (DDBJ, Mishima, Japan) .
The genes described in the literature references cited can be used according to the invention. It is also possible to use alleles of the genes which result from the degeneracy of the genetic code or from neutral sense mutations . The use of endogenous genes is preferred.
The term "endogenous genes" or "endogenous nucleotide sequences" is to be understood as meaning the genes or alleles, or nucleotide sequences, present in the population of a species.
Enhancement can be achieved for example by increasing the expression of the genes or enhancing the catalytic properties of the proteins. Both measures may optionally be combined.
The concentration of the transport protein coded for by the polynucleotide mglB can be determined by the method described by Richarme and Caldas (Journal of Biological Chemistry 272, 15607-15612 (1997)).
Over-expression can be achieved by increasing the copy number of the appropriate genes or mutating the promoter and regulatory region or the ribosome binding site located upstream from the structural gene. Expression cassettes incorporated upstream from the structural gene work in the same way. Inducible promoters additionally make it possible to increase expression in the course of L- threonine production by fermentation. Measures for prolonging the life of the RNA also improve expression. Furthermore, the enzyme activity is also enhanced by preventing the degradation of the enzyme protein. The genes or gene constructs can either be located in plasmids of variable copy number or be integrated and amplified in the chromosome. Alternatively, it is also possible to achieve over-expression of the genes in question by changing the composition of the media and the culture technique.
Those skilled in the art will find relevant instructions inter alia in Chang and Cohen (Journal of Bacteriology 134, 1141-1156 (1978)), Hartley and Gregori (Gene 13, 347-353 (1981)), A ann and Brosius (Gene 40, 183-190 (1985)), de Broer et al . (Proceedings of the National Academy of Sciences of the United States of America 80, 21-25 (1983)), LaVallie et al . (BIO/TECHNOLOGY 11, 187-193 (1993)), PCT/US97/13359, Llosa et al . (Plas id 26, 222-224 (1991)), Quandt and Klipp (Gene 80, 161-169 (1989)), Hamilton (Journal of Bacteriology 171, 4617-4622 (1989)), Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195
(1998)) and well-known textbooks on genetics and molecular biology.
Plasmid vectors replicable in Enterobacteriaceae, e.g. cloning vectors derived from pACYC184 (Bartolome et al . ; Gene 102, 75-78 (1991)), pTrc99A (Amann et al . ; Gene 69,
301-315 (1988)) or pSClOl derivatives (Vocke and Bastia;
Proceedings of the National Academy of Sciences USA 80
(21), 6557-6561 (1983)), can be used. In one process according to the invention, it is possible to use a strain transformed with a plasmid vector, said plasmid vector carrying at least one nucleotide sequence coding for the mglB gene.
Also, mutations which affect the expression of the appropriate genes can be transferred to different strains by sequence exchange (Hamilton et al . (Journal of
Bacteriology 171, 4617-4622 (1989)), conjugation or transduction.
Furthermore, for the production of L-amino acids, especially L-threonine, with strains of the family Enterobacteriaceae, it can be advantageous not only to enhance the mglB gene but also to enhance one or more enzymes of the known threonine biosynthetic pathway, or enzymes of the anaplerotic metabolism, or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate, or glycolytic enzymes, or PTS enzymes or enzymes of sulfur metabolism. The use of endogenous genes is preferred.
Thus, for example, one or more genes selected from the group comprising:
• the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765) ,
• the pyc gene coding for pyruvate carboxylase (DE-A-19 831 609),
• the pps gene coding for phosphoenolpyruvate synthase (Molecular and General Genetics 231, 332 (1992)),
• the ppc gene coding for phosphoenolpyruvate carboxylase (Gene 31, 279-283 (1984) ) ,
• the pntA and pntB genes coding for transhydrogenase
(European Journal of Biochemistry 158, 647-653 (1986)),
• the rhtB gene for homoserine resistance (EP-A-0 994 190) ,
• the mqo gene coding for malate:quinone oxidoreductase (DE 100 348 33.5) ,
• the rhtC gene for threonine resistance (EP-A-1 013 765) ,
• the thrE gene of Corynebacterium glutamicum coding for threonine export (DE 100 264 94.8), • the gdhA gene coding for glutamate dehydrogenase (Nucleic Acids Research 11, 5257-5266 (1983); Gene 23, 199-209 (1983)) ,
• the hns gene coding for DNA binding protein HLP-II (Molecular and General Genetics 212, 199-202 (1988)),
• the pgm gene coding for phosphoglucomutase (Journal of Bacteriology 176, 5847-5851 (1994)),
• the fba gene coding for fructose biphosphate aldolase (Biochemical Journal 257, 529-534 (1989)),
• the ptsHIcrr operon coding for phosphohistidine protein hexose phosphotransferase, PTS enzyme I and the glucose- specific IIA component (Journal of Biological Chemistry 262, 16241-16253 (1987)),
• the ptsG gene coding for the glucose-specific IIBC component (Journal of Biological Chemistry 261, 16398- 16403 (1986)),
• the lrp gene coding for the regulator of the leucine regulon (Journal of Biological Chemistry 266, 10768-10774 (1991)),
• the csrA gene coding for the global regulator (Journal of Bacteriology 175, 4744-4755 (1993)),
• the fadR gene coding for the regulator of the fad regulon (Nucleic Acids Research 16, 7995-8009 (1988)),
• the iclR gene coding for the regulator of the central intermediary metabolism (Journal of Bacteriology 172,
2642-2649 (1990)),
• the mopB gene coding for the 10 kd chaperone (Journal of Biological Chemistry 261, 12414-12419 (1986)), which is also known as groES, • the ahpCF operon coding for the alkyl hydroperoxide reductase subunits (Proceedings of the National Academy of Sciences USA 92, 7617-7621 (1995)),
• the cysK gene coding for cysteine synthase A (Journal of Bacteriology 170, 3150-3157 (1988)),
• the cysB gene coding for the regulator of the cys regulon (Journal of Biological Chemistry 262, 5999-6005 (1987)), and [sic]
• the cysJIH operon coding for the flavoprotein of NADPH sulfite reductase, the hemoprotein of NADPH sulfite reductase and adenylyl sulfate reductase (Journal of Biological Chemistry 264, 15796-15808 (1989), Journal of Biological Chemistry 264, 15726-15737 (1989)),
• the phoB gene of the phoBR operon coding for the PhoB positive regulator of the pho regulon (Journal of
Molecular Biology 190 (1), 37-44 (1986)),
• the phoR gene of the phoBR operon coding for the sensor protein of the pho regulon (Journal of Molecular Biology 192 (3), 549-556 (1986)),
• the phoE gene coding for protein E of the outer cell membrane (Journal of Molecular Biology 163 (4) , 513-532 (1983) ) ,
• the pykF gene coding for fructose-stimulated pyruvate kinase I (Journal of Bacteriology 177 (19), 5719-5722 (1995)),
• the pfkB gene coding for 6-phosphofructokinase II (Gene 28 (3), 337-342 (1984)),
• the malE gene coding for the periplasmatic binding protein of maltose transport (Journal of Biological Chemistry 259 (16), 10606-10613 (1984)), • the rseA gene of the rseABC operon coding for a membrane protein with anti-sigmaE activity (Molecular Microbiology 24 (2), 355-371 (1997)),
• the rseC gene of the rseABC operon coding for a global regulator of the sigmaE factor (Molecular Microbiology 24 (2), 355-371 (1997)),
• the sodA gene coding for superoxide dismutase (Journal of Bacteriology 155 (3), 1078-1087 (1983)),
• the sucA gene of the sucABCD operon coding for the decarboxylase subunit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2) , 351-359 (1984)) ,
• the sucB gene of the sucABCD operon coding for the dihydrolipoyl transsuccinase E2 subunit of 2- ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2), 361-374 (1984)),
• the sucC gene of the sucABCD operon coding for the β subunit of succinyl-CoA synthetase (Biochemistry 24 (22), 6245-6252 (1985)), and
• the sucD gene of the sucABCD operon coding for the α subunit of succinyl-CoA synthetase (Biochemistry 24 (22), 6245-6252 (1985))
can be simultaneously enhanced and, in particular, overexpressed .
Furthermore, for the production of L-amino acids, especially L-threonine, it can be advantageous not only to enhance the mglB gene but also to attenuate and, in particular, switch off one or more genes selected from the group comprising: • the tdh gene coding for threonine dehydrogenase (Ravnikar and Somerville, Journal of Bacteriology 169, 4716-4721 (1987)) ,
• the mdh gene coding for malate dehydrogenase (E.C. 1.1.1.37) (Vogel et al . , Archives in Microbiology 149, 36-42 (1987)),
• the gene product of the open reading frame (orf) yjfA (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
• the gene product of the open reading frame (orf) ytfP (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
• the pckA gene coding for the enzyme phosphoenolpyruvate carboxykinase (Medina et al . (Journal of Bacteriology 172, 7151-7156 (1990)),
• the poxB gene coding for pyruvate oxidase (Grabau and Cronan (Nucleic Acids Research 14 (13), 5449-5460 (1986) ) ,
• the aceA gene coding for the enzyme isocitrate lyase (Matsuoko and McFadden, Journal of Bacteriology 170,
4528-4536 (1988)),
• the dgsA gene coding for the DgsA regulator of the phosphotransferase system (Hosono et al . , Bioscience, Biotechnology and Biochemistry 59, 256-261 (1995)), which is also known as the mlc gene,
• the fruR gene coding for the fructose repressor (Jahreis et al . , Molecular and General Genetics 226, 332-336 (1991)), which is also known as the era gene,
• the rpoS gene coding for the sigma38 factor (WO 01/05939) , which is also known as the katF gene, the aspA gene coding for aspartate ammonium lyase (aspartase) (Nucleic Acids Research 13 (6), 2063-2074 (1985)), and
• the aceB gene coding for malate synthase A (Nucleic Acids Research 16 (19), 9342 (1988)),
or reduce the expression.
In this context the term "attenuation" describes the decrease or switching-off of the intracellular activity, in a microorganism, of one or more enzymes (proteins) coded for by the appropriate DNA, for example by using a weak promoter or using a gene or allele which codes for an appropriate enzyme with a low activity or inactivates the appropriate enzyme (protein) or gene, and optionally combining these measures .
The attenuation measures generally reduce the activity or concentration of the appropriate protein to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
Furthermore, for the production of L-amino acids, especially L-threonine, it can be advantageous not only to enhance the mglB gene but also to switch off unwanted secondary reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982) .
The microorganisms prepared according to the invention can be cultivated by the batch process, the fed batch process or the repeated fed batch process. A summary of known cultivation methods is provided in the textbook by Chmiel (Bioprozesstechnik 1. Einfuhrung in die Bioverfahrenstechnik (Bioprocess Technology 1. Introduction to Bioengineering) (Gustav Fischer Verlag, Stuttgart, 1991) ) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Bioreactors and Peripheral Equipment) (Vieweg Verlag, Brunswick/Wiesbaden, 1994) ) .
The culture medium to be used must appropriately meet the demands of the particular strains. Descriptions of culture media for various microorganisms can be found in "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington DC, USA, 1981) .
Carbon sources which can be used are sugars and carbohydrates, e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, e.g. palmitic acid, stearic acid and linoleic acid, alcohols, e.g. glycerol and ethanol , and organic acids, e.g. acetic acid. These substances can be used individually or as a mixture.
Nitrogen sources which can be used are organic nitrogen- containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources can be used individually or as a mixture.
Phosphorus sources which can be used are phosphoric acid, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium salts . The culture medium must also contain metal salts, e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such as amino acids and vitamins can be used in addition to the substances mentioned above. Suitable precursors can also be added to the culture medium. Said feed materials can be added to the culture all at once or fed in appropriately during cultivation.
The pH of the culture is controlled by the appropriate use of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds such as phosphoric acid or sulfuric acid. Foaming can be controlled using antifoams such as fatty acid polyglycol esters. The stability of plasmids can be maintained by adding suitable selectively acting substances, e.g. antibiotics, to the medium. Aerobic conditions are maintained by introducing oxygen or oxygen-containing gaseous mixtures, e.g. air, into the culture. The temperature of the culture is normally 25aC to 452C and preferably 302C to 40 -C . The culture is continued until the formation of L-amino acids or L-threonine has reached a maximum. This objective is normally achieved within 10 hours to 160 hours.
L-Amino acids can be analyzed by means of anion exchange chromatography followed by ninhydrin derivation, as described by Spackman et al . (Analytical Chemistry 30, 1190 (1958)), or by reversed phase HPLC, as described by Lindroth et al . (Analytical Chemistry 51, 1167-1174 (1979) ) .
The process according to the invention is used for the preparation of L-amino acids, e.g. L-threonine, L- isoleucine, L-valine, L-methionine, L-homoserine and L- lysine, especially L-threonine, by fermentation.
The present invention is illustrated in greater detail below with the aid of Examples.
The minimum medium (M9) and complete medium (LB) used for Escherichia coli are described by J.H. Miller (A Short Course in Bacterial Genetics (1992), Cold Spring Harbor Laboratory Press) . The isolation of plasmid DNA from Escherichia coli and all the techniques for restriction, ligation, Klenow treatment and alkaline phosphatase treatment are carried out according to Sambrook et al . (Molecular Cloning - A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press) . Unless described otherwise, the transformation of Escherichia coli is carried out according to Chung et al . (Proceedings of the National Academy of Sciences of the United States of America 86, 2172-2175 (1989)).
The incubation temperature in the preparation of strains and transformants is 37°C.
Example 1
Construction of expression plasmid pTrc99AmglB
The mglB gene from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides . The nucleotide sequence of the mglB gene in E. coli K12 MG1655 (Accession Number AE000304, Blattner et al. (Science 277, 1453-1474 (1997)) is used as the starting material to synthesize PCR primers (MWG Biotech, Ebersberg, Germany) . The sequences of the 5' ends of the primers are modified to create recognition sites for restriction enzymes. The recognition sequences for Xbal and Hindlll, which are underlined in the nucleotide sequence shown below, are chosen for the mglBl and mglB2 primers respectively:
mglBl: 5'-CCTGCTCTAGATAAACCGGAGATACCATG-3 ' (SEQ ID No . 1)
mglB2 : 5'-CCGAAGCTTGTTGGCCATACAATAAGGGCG-3 ' (SEQ ID No . 2)
The chromosomal E. coli K12 MG1655 DNA used for the PCR is isolated with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions. An approx. 1100 bp DNA fragment can be amplified with the specific primers under standard PCR conditions (Innis et al . (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) using pfu DNA polymerase (Promega Corporation, Madison, USA) . The PCR product is cleaved with the restriction enzymes Xbal and Hindlll and ligated with vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) that has been digested with the enzymes Xbal and Hindlll. The E. coli strain XLl-Blue MRF ' (Stratagene, La Jolla, USA) is transformed with the ligation mixture and plasmid-carrying cells are selected on LB agar supplemented with 50 μg/ml of ampicillin. The success of the cloning can be demonstrated, after isolation of the plasmid DΝA, by control cleavage with the enzymes Xbal, Hindlll, EcoRI and Hpal . The plasmid is called pTrc99AmglB (Figure 1) .
Example 2
Preparation of L-threonine with the strain MG442/pTrc99AmglB
The L-threonine-producing E. coli strain MG442 is described in patent US-A-4, 278 , 765 and is deposited in the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia) as CMIM B-1628.
The strain MG442 is transformed with expression plasmid pTrc99AmglB, described in Example 1, and with vector pTrc99A and plasmid-carrying cells are selected on LB agar supplemented with 50 μg/ml of ampicillin. This procedure yields the strains MG442/pTrc99AmglB and MG442/pTrc99A. Chosen individual colonies are then multiplied further on minimum medium of the following composition: 3.5 g/1 of Na2HP04-2H20, 1.5 g/1 of KH2P04, 1 g/1 of NH4C1, 0.1 g/1 of MgS04-7H20, 2 g/1 of glucose, 20 g/1 of agar, 50 mg/1 of ampicillin. The formation of L-threonine is verified in 10 ml batch cultures contained in 100 ml conical flasks. This is done by inoculating 10 ml of preculture medium of the following composition: 2 g/1 of yeast extract, 10 g/1 of (NH4)2S04, 1 g/1 of KH2P0 , 0.5 g/1 of MgS04-7H20, 15 g/1 of CaC03, 20 g/1 of glucose, 50 mg/1 of ampicillin, and incubating for 16 hours at 37°C and 180 rpm on an ESR incubator from Kuhner AG (Birsfelden, Switzerland) . 250 μl of each of these precultures are transferred to 10 ml of production medium (25 g/1 of (NH )2S0 , 2 g/1 of KH2P0 , 1 g/1 of MgS04-7H20, 0.03 g/1 of FeS04-7H20, 0.018 g/1 of MnS0 -lH20, 30 g/1 of CaC03, 20 g/1 of glucose, 50 mg/1 of ampicillin) and incubated for 48 hours at 37°C. The formation of L-threonine by the original strain MG442 is verified in the same way except that no ampicillin is added to the medium. After incubation the optical density (OD) of the culture suspension is determined using an LP2W photometer from Dr. Lange (Berlin, Germany) at a measurement wavelength of 660 nm.
The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by means of ion exchange chromatography and postcolumn reaction with ninhydrin detection.
Table 1 shows the result of the experiment
Table 1
Figure imgf000020_0001
Brief Description of the Figure:
• Figure 1: Map of plasmid pTrc99AmglB containing the mglB gene The indicated lengths are to be understood as approximate. The abbreviations and symbols used are defined as follows:
• Amp: ampicillin resistance gene
• lad : gene for the repressor protein of the trc promoter
• Ptrc: trc promoter region, IPTG-inducible
• mglB: coding region of the mglB gene
• 5S: 5S rRNA region
• rrnBT: rRNA terminator region
The abbreviations for the restriction enzymes are defined as follows:
• EcoRI : restriction endonuclease from Escherichia coli
• Hindlll: restriction endonuclease from Haemophilus influenzae
• Hpal : restriction endonuclease from Haemophilus parainfluenzae
• Xbal: restriction endonuclease from Xanthomonas badrii

Claims

What is claimed is:
1. A process for the preparation of L-amino acids, especially L-threonine, characterized in that the following steps are carried out:
a) fermentation of microorganisms of the family
Enterobacteriaceae which produce the desired L- amino acid and in which the mglB gene, or nucleotide sequences coding therefor, is (are) enhanced and, in particular, overexpressed,
b) enrichment of the desired L-amino acid in the medium or in the cells of the microorganisms, and
c) isolation of the desired L-amino acid, where constituents of the fermentation broth, and/or all or part (> 0 to 100%) of the biomass, optionally remain in the product.
2. The process according to claim 1, characterized in that microorganisms are used in which other genes of the biosynthetic pathway of the desired L-amino acid are additionally enhanced.
3. The process according to claim 1, characterized in that microorganisms are used in which the metabolic pathways which reduce the formation of the desired L- amino acid are at least partially switched off.
4. The process according to claim 1, characterized in that the expression of the polynucleotide (s) coding for the mglB gene is increased.
5. The process according to claim 1, characterized in that the regulatory and/or catalytic properties of the polypeptide (protein) coded for by the polynucleotide mglB are improved or enhanced. The process according to claim 1, characterized in that microorganisms of the family Enterobacteriaceae in which additionally one or more genes selected from the group comprising:
6.1 the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
6.2 the pyc gene coding for pyruvate carboxylase,
6.3 the pps gene coding for phosphoenolpyruvate synthase,
6. the ppc gene coding for phosphoenolpyruvate carboxylase,
6.5 the pntA and pntB genes coding for transhydrogenase,
6.6 the rhtB gene for homoserine resistance,
6.7 the mqo gene coding for malate :quinone oxidoreductase,
6.8 the rhtC gene for threonine resistance,
6.9 the thrE gene coding for threonine export,
6.10 the gdhA gene coding for glutamate dehydrogenase,
6.11 the hns gene coding for DNA binding protein HLP- II,
6.12 the pgm gene coding for phosphoglucomutase,
6.13 the fba gene coding for fructose biphosphate aldolase,
6.14 the ptsHIcrr operon coding for phosphohistidine protein hexose phosphotransferase, PTS enzyme I and the glucose-specific IIA component,
6.15 the ptsG gene coding for the glucose-specific IIBC component,
6.16 the lrp gene coding for the regulator of the leucine regulon,
6.17 the csrA gene coding for the global regulator,
6.18 the fadR gene coding for the regulator of the fad regulon,
6.19 the iclR gene coding for the regulator of the central intermediary metabolism,
6.20 the mopB gene coding for the 10 kd chaperone,
6.21 the ahpCF operon coding for the alkyl hydroperoxide reductase subunits,
6.22 the cysK gene coding for cysteine synthase A,
6.23 the cysB gene coding for the regulator of the cys regulon,
6.24 the cysJIH operon coding for the flavoprotein of NADPH sulfite reductase, the hemoprotein of NADPH sulfite reductase and adenylyl sulfate reductase,
6.25 the phoB gene coding for the PhoB positive regulator of the pho regulon,
6.26 the phoR gene coding for the sensor protein of the pho regulon,
6.27 the phoE gene coding for protein E of the outer cell membrane,
6.28 the pykF gene coding for fructose-stimulated pyruvate kinase I ,
6.29 the pfkB gene coding for 6-phosphofructokinase II,
6.30 the malE gene coding for the periplasmatic binding protein of maltose transport,
6.31 the rseA gene coding for a membrane protein with anti-sigmaE activity,
6.32 the rseC gene coding for a global regulator of the sigmaE factor,
6.33 the sodA gene coding for superoxide dismutase,
6.34 the sucA gene coding for the decarboxylase subunit of 2-ketoglutarate dehydrogenase,
6.35 the sucB gene coding for the dihydrolipoyl transsuccinase E2 subunit of 2-ketoglutarate dehydrogenase,
6.36 the sucC gene coding for the β subunit of succinyl-CoA synthetase, and
6.37 the sucD gene coding for the α subunit of succinyl-CoA synthetase
is (are) simultaneously enhanced and, in particular, overexpressed are fermented for the preparation of L- amino acids .
7. The process according to claim 1, characterized in that microorganisms of the family Enterobacteriaceae in which additionally one or more genes selected from the group comprising:
7.1 the tdh gene coding for threonine dehydrogenase,
7.2 the mdh gene coding for malate dehydrogenase,
7.3 the gene product of the open reading frame (orf) YJfA,
7.4 the gene product of the open reading frame (orf) ytfP,
7.5 the pckA gene coding for phosphoenolpyruvate carboxykinase,
7.6 the poxB gene coding for pyruvate oxidase,
7.7 the aceA gene coding for isocitrate lyase,
7.8 the dgsA gene coding for the DgsA regulator of the phosphotransferase system,
7.9 the fruR gene coding for the fructose repressor,
7.10 the rpoS gene coding for the sigma38 factor,
7.11 the aspA gene coding for aspartate ammonium lyase (aspartase) , and
7.12 the aceB gene coding for malate synthase A
is (are) simultaneously attenuated and, in particular, switched off, or the expression is reduced, are fermented for the preparation of L-amino acids .
8. Microorganisms of the family Enterobacteriaceae, especially of the genus Escherichia, in which the mglB gene, or nucleotide sequences coding therefor, is (are) enhanced and, in particular, overexpressed.
PCT/EP2003/001997 2002-03-13 2003-02-27 Process for the preparation of l-amino acids using strains of the family enterobacteriaceae WO2003076627A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE60321891T DE60321891D1 (en) 2002-03-13 2003-02-27 PROCESS FOR THE PREPARATION OF L-THREONINE USING MEASURES OF THE ENTEROBACTERIACEAE FAMILY
EP03708152A EP1483387B1 (en) 2002-03-13 2003-02-27 Process for the preparation of l-threonine using strains of the family enterobacteriaceae
US10/937,554 US20050095687A1 (en) 2002-03-13 2004-09-10 Process for the preparation of L-amino acids using strains of the family enterobacteriaceae

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10210966.4 2002-03-13
DE2002110966 DE10210966A1 (en) 2002-03-13 2002-03-13 Preparation of amino acids, particularly threonine, useful e.g. in animal nutrition, by growing Enterobacteriaceae having increased activity of the mglB gene
US36582902P 2002-03-21 2002-03-21
US60/365,829 2002-03-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/937,554 Continuation US20050095687A1 (en) 2002-03-13 2004-09-10 Process for the preparation of L-amino acids using strains of the family enterobacteriaceae

Publications (1)

Publication Number Publication Date
WO2003076627A1 true WO2003076627A1 (en) 2003-09-18

Family

ID=27806082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001997 WO2003076627A1 (en) 2002-03-13 2003-02-27 Process for the preparation of l-amino acids using strains of the family enterobacteriaceae

Country Status (5)

Country Link
US (1) US20050095687A1 (en)
EP (1) EP1483387B1 (en)
AT (1) ATE399863T1 (en)
DE (1) DE60321891D1 (en)
WO (1) WO2003076627A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116622600A (en) * 2022-02-14 2023-08-22 廊坊梅花生物技术开发有限公司 Construction method of threonine producing strain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278765A (en) * 1978-06-30 1981-07-14 Debabov Vladimir G Method for preparing strains which produce aminoacids
EP0643135A1 (en) * 1992-11-10 1995-03-15 Ajinomoto Co., Inc. Process for producing l-threonine by fermentation
WO1999053035A1 (en) * 1998-04-13 1999-10-21 The University Of Georgia Research Foundation, Inc. Pyruvate carboxylase overexpression for enhanced production of oxaloacetate-derived biochemicals in microbial cells
EP0994190A2 (en) * 1998-10-13 2000-04-19 Ajinomoto Co., Inc. DNA conferring L-homoserine resistance to bacteria, and its use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278765A (en) * 1978-06-30 1981-07-14 Debabov Vladimir G Method for preparing strains which produce aminoacids
EP0643135A1 (en) * 1992-11-10 1995-03-15 Ajinomoto Co., Inc. Process for producing l-threonine by fermentation
WO1999053035A1 (en) * 1998-04-13 1999-10-21 The University Of Georgia Research Foundation, Inc. Pyruvate carboxylase overexpression for enhanced production of oxaloacetate-derived biochemicals in microbial cells
EP0994190A2 (en) * 1998-10-13 2000-04-19 Ajinomoto Co., Inc. DNA conferring L-homoserine resistance to bacteria, and its use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEXANDER D M ET AL.: "Carbohydrate uptake genes in Escherichia coli are induced by carbon starvation.", CURRENT MICROBIOLOGY, vol. 27, no. 6, 1993, pages 335 - 340, XP008018907, ISSN: 0343-8651 *
HARAYAMA S ET AL.: "Characterization of the mgl operon of Escherichia coli by transposon mutagenesis and molecular cloning.", JOURNAL OF BACTERIOLOGY, vol. 153, no. 1, January 1983 (1983-01-01), pages 408 - 415, XP008018905, ISSN: 0021-9193 *
HOGG R W ET AL.: "Nucleotide sequence and analysis of the mgl operon of Escherichia coli K12.", MOLECULAR & GENERAL GENETICS, vol. 229, no. 3, October 1991 (1991-10-01), pages 453 - 459, XP001149195, ISSN: 0026-8925 *
JETTEN M S M ET AL.: "Recent advances in the physiology and genetics of amino acid-producing bacteria.", CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 15, no. 1, 1995, pages 73 - 103, XP000613291, ISSN: 0738-8551 *
KRAEMER R: "Genetic and physiological approaches for the production of amino acids", JOURNAL OF BIOTECHNOLOGY, vol. 45, no. 1, 1996, pages 1 - 21, XP002178648, ISSN: 0168-1656 *
MICHAL G: "Biochemical pathways: an atlas of biochemistry and molecular biology", 1999, JOHN WILEY & SONS INC. AND SPEKTRUM AKADEMISCHER VERLAG, NEW YORK - HEIDELBERG, ISBN: 0-471-33130-9, XP002242199 *
MÜLLER N ET AL.: "Cloning of mglB, the structural gene for the galactose-binding protein of Salmonella typhimurium and Escherichia coli.", MOLECULAR & GENERAL GENETICS, vol. 185, no. 3, 1982, pages 473 - 480, XP008018906, ISSN: 0026-8925 *
NOTLEY-MCROBB L ET AL.: "Adaptive mgl-regulatory mutations and genetic diversity evolving in glucose-limited Escherichia coli populations", ENVIRONMENTAL MICROBIOLOGY, vol. 1, no. 1, February 1999 (1999-02-01), pages 33 - 43, XP001147506, ISSN: 1462-2912 *

Also Published As

Publication number Publication date
ATE399863T1 (en) 2008-07-15
US20050095687A1 (en) 2005-05-05
EP1483387B1 (en) 2008-07-02
EP1483387A1 (en) 2004-12-08
DE60321891D1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
EP2083080B1 (en) Process for the preparation of L-threonine using strains of the Enterobacteriaceae family which contain an enhanced rseC gene
EP1404821A2 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family
EP1446493A2 (en) A process for the production of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced fadr or iclr gene
US20050095688A1 (en) Process for the preparation of L-amino acids using strains of the family Enterobacteriaceae
EP1483392B1 (en) Process for the preparation of l-amino acids using strains of the family enterobacteriaceae
US20040241814A1 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced rsea or rsec gene
EP1448778A1 (en) Process for the preparation of non-aromatic l-amino acids using strains of the enterobacteriaceae family
EP1483387B1 (en) Process for the preparation of l-threonine using strains of the family enterobacteriaceae
EP1382685A2 (en) Process for the fermentative preparation of L-amino acids using strains of the enterobacteriaceae family with overexpressed rseB gene
EP1483394A2 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CN KR MX PL US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003708152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10937554

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003708152

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003708152

Country of ref document: EP